Jason A. Leverone's Insider Trades & SAST Disclosures

Jason A. Leverone's most recent trade in OnKure Therapeutics Inc. - Ordinary Shares - Class A was a trade of 303 Class A Common Stock done at an average price of $2.4 . Disclosure was reported to the exchange on June 23, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Sale of securities on an exchange or to another person at price $ 2.38 per share. 23 Jun 2025 303 12,906 - 2.4 722 Class A Common Stock
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Sale of securities on an exchange or to another person at price $ 2.67 per share. 04 Apr 2025 1,844 13,209 - 2.7 4,925 Class A Common Stock
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Sale of securities on an exchange or to another person at price $ 3.33 per share. 04 Apr 2025 1,278 15,053 - 3.3 4,253 Class A Common Stock
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 65,000 65,000 - - Employee Stock Option (right to buy)
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 130,611 130,611 - - Employee Stock Option (right to buy)
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 16,331 16,331 - - Class A Common Stock
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 5,781 5,781 - - Employee Stock Option (right to buy)
OnKure Therapeutics Inc. -...
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 5,322 5,322 - - Employee Stock Option (right to buy)
Viridian Therapeutics Inc
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Jan 2021 311,785 311,785 - - Employee Stock Option (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades